Alzheimer's disease Trials in Wellington, United States
Conditions / Alzheimer's disease / Wellington, United States
Research into Alzheimer's disease spans multiple therapeutic approaches and trial phases.
14 total trials for this combination
Showing top 10 of 14 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04592874 | A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease | COMPLETED | PHASE2 |
| NCT06585787 | A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | RECRUITING | PHASE3 |
| NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03444870 | Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) | TERMINATED | PHASE3 |
| NCT06335173 | A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03446001 | Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment | COMPLETED | PHASE3 |
| NCT04619420 | A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04374253 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) | TERMINATED | PHASE3 |
| NCT05575076 | Open-label Extension for Phase 3 Clinical Trials of Simufilam | TERMINATED | PHASE3 |
| NCT05026177 | Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease | TERMINATED | PHASE3 |